Total Payments
$50,606
2024 Payments
$310.61
Companies
23
Transactions
228
Medicare Patients
810
Medicare Billing
$174,779
Payment Breakdown by Category
Research$45,543 (90.0%)
Food & Beverage$4,274 (8.4%)
Travel$758.23 (1.5%)
Education$31.27 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,543 | 4 | 90.0% |
| Food and Beverage | $4,274 | 217 | 8.4% |
| Travel and Lodging | $758.23 | 5 | 1.5% |
| Education | $31.27 | 2 | 0.1% |
Payments by Type
Research
$45,543
4 transactions
General
$5,063
224 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $47,147 | 57 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $989.19 | 35 | $0 (2024) |
| Lundbeck LLC | $502.55 | 27 | $0 (2024) |
| ABBVIE INC. | $497.79 | 34 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $183.96 | 8 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $174.06 | 9 | $0 (2024) |
| Shire North American Group Inc | $173.60 | 10 | $0 (2019) |
| Avanir Pharmaceuticals, Inc. | $140.47 | 9 | $0 (2020) |
| Vanda Pharmaceuticals Inc. | $100.32 | 3 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $95.46 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $310.61 | 13 | ABBVIE INC. ($67.93) |
| 2023 | $726.13 | 39 | AbbVie Inc. ($291.03) |
| 2022 | $307.41 | 19 | ABBVIE INC. ($138.83) |
| 2021 | $23.18 | 1 | Lundbeck LLC ($23.18) |
| 2020 | $505.94 | 32 | Otsuka America Pharmaceutical, Inc. ($142.39) |
| 2019 | $549.89 | 32 | Allergan Inc. ($120.17) |
| 2018 | $2,036 | 55 | Allergan Inc. ($1,284) |
| 2017 | $46,147 | 37 | Allergan Inc. ($45,601) |
All Payment Transactions
228 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $32.48 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: PSYCHIATRY | ||||||
| 09/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: PSYCHIATRY | ||||||
| 06/05/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $23.53 | General |
| 04/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: NEUROSCIENCE | ||||||
| 04/02/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: Psychology/Psychiatric | ||||||
| 02/20/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: CNS | ||||||
| 02/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: NEUROSCIENCE | ||||||
| 01/30/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.27 | General |
| Category: PSYCHIATRY | ||||||
| 01/09/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $33.46 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/19/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: Central Nervous System | ||||||
| 12/05/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.78 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: PSYCHIATRY | ||||||
| 09/13/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: PSYCHIATRY | ||||||
| 09/05/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.02 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $35,114 | 2 |
| A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $7,937 | 1 |
| AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD. | Allergan Inc. | $2,491 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 140 | 455 | $54,360 | $35,202 |
| 2022 | 5 | 181 | 548 | $62,155 | $43,213 |
| 2021 | 4 | 215 | 593 | $60,090 | $38,323 |
| 2020 | 5 | 274 | 826 | $87,110 | $58,041 |
Total Patients
810
Total Services
2,422
Medicare Billing
$174,779
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 296 | $29,860 | $17,019 | 57.0% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 20 | 146 | $21,900 | $16,159 | 73.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 13 | 13 | $2,600 | $2,024 | 77.9% |
| 90837 | Psychotherapy, 1 hour | Office | 2022 | 24 | 182 | $27,300 | $20,526 | 75.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 283 | $22,640 | $14,558 | 64.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 42 | $4,640 | $3,360 | 72.4% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 21 | 25 | $4,375 | $2,716 | 62.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 16 | 16 | $3,200 | $2,053 | 64.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 164 | 428 | $34,240 | $21,232 | 62.0% |
| 90837 | Psychotherapy, 60 minutes | Office | 2021 | 20 | 134 | $20,100 | $13,017 | 64.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 13 | 13 | $2,600 | $2,080 | 80.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 18 | 18 | $3,150 | $1,995 | 63.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 180 | 524 | $41,920 | $27,581 | 65.8% |
| 90837 | Psychotherapy, 60 minutes | Office | 2020 | 35 | 204 | $30,600 | $21,421 | 70.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 49 | $5,390 | $3,976 | 73.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 25 | 25 | $5,000 | $2,621 | 52.4% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2020 | 23 | 24 | $4,200 | $2,442 | 58.2% |
About Dr. Robert Earle, MD
Dr. Robert Earle, MD is a Psychiatry healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750506986.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Earle, MD has received a total of $50,606 in payments from pharmaceutical and medical device companies, with $310.61 received in 2024. These payments were reported across 228 transactions from 23 companies. The most common payment nature is "" ($45,543).
As a Medicare-enrolled provider, Earle has provided services to 810 Medicare beneficiaries, totaling 2,422 services with total Medicare billing of $174,779. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Houston, TX
- Active Since 04/14/2007
- Last Updated 12/14/2015
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1750506986
Products in Payments
- FETZIMA (Drug) $7,937
- REXULTI (Drug) $1,249
- VRAYLAR (Drug) $1,028
- TRINTELLIX (Drug) $226.61
- INGREZZA (Drug) $183.96
- NUEDEXTA (Drug) $140.47
- BRINTELLIX (Drug) $103.56
- Fanapt (Drug) $100.32
- LATUDA (Drug) $91.21
- Auvelity (Drug) $87.22
- ABILIFY MYCITE (Drug) $85.88
- MYDAYIS (Drug) $84.99
- Subvenite (Drug) $80.22
- Austedo XR (Drug) $71.99
- BELSOMRA (Drug) $62.75
- VYVANSE (Drug) $55.64
- CAPLYTA (Drug) $42.57
- Trintellix (Drug) $41.20
- INVEGA SUSTENNA (Drug) $33.66
- COBENFY (Drug) $32.48
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Houston
Dr. Lawrence Ginsberg, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Mazhar Khowaja
Psychiatry — Payments: $897,870
Psychiatry $897,870
Barry Gritz, M.d, M.D
Psychiatry — Payments: $731,949
Psychiatry $731,949
Dr. Frank Chen, Md Pa, MD PA
Psychiatry — Payments: $721,138
Psychiatry $721,138
Dr. Aaron Peterson, Do, DO
Psychiatry — Payments: $549,804
Psychiatry $549,804
Ayesha Rashid, M.d, M.D
Psychiatry — Payments: $445,948
Psychiatry $445,948